New

ASPIRA-aXAY
with blue light protection

7.0 mm optic preloaded

ASPIRA-aXA
XL optic – vision without limits

Read more

ASPIRA-aXA

Pseudophakic reliability for you and your patients

The innovative XL optic of the ASPIRA-aXA combines the advantages of a 7.0 mm optic with the stability of the new cut-out haptic design. This posterior-chamber IOL an be conveniently implanted using small-incision technology while adhering to surgical routine.

Overview of topics

Monofocal ASPIRA-aXA

Personal
Contact

TypeMonofocal 1-piece posterior chamber lens, foldable
Optic diameter 7.0 mm
Total diameter 11.0 mm
Material Glistening-free, hydrophilic acrylic, UV blocker
Optic features Aspherical anterior surface, aberration-free, 360° LEC barrier,
HD optic
Haptic design Cut-out haptics
Constants for IOL calculationPlease click here
XL diopter range ASPIRA-aXAPreloaded SAFELOADER®
10.0 to 30.0 D in 0.5 D steps

Compact Line
-10.0 to 9.0 D in 1.0 D steps
10.0 to 30.0 in 0.5 D steps

XL diopter range ASPIRA-aXAY YellowPreloaded SAFELOADER®
10.0 to 30.0 D in 0.5 D steps
eIFUASPIRA-aXA/-aXAY
SAFELOADER®

Preloaded implantation system
SIMPLE. INTUITIVE. FAST.

SAFELOADER®

ASPIRA-aXA

MORE THAN A CONVENTIONAL IOL

The XL optic design of the posterior chamber IOL with its extended optic diameter of 7.0 mm

and permits implantation through small incisions at the same time.

ASPIRA-aXA

THE ROUTINE REMAINS

ASPIRA-aXA

PROVIDES THE SOLUTION

ASPIRA-aXA provides a custom solution for the most diverse needs. Possible applications range from standard cataract surgery to refractive surgery and combined interventions in retinal surgery.

ASPIRA-aXA

FULFILLING PATIENT REQUIREMENTS

Advantages of an XL optic

LARGE PUPILS

With its XL optic the ASPIRA-aXA provides an ideal treatment option even under poor lighting conditions.

20% of cataract patients have a scotopic pupil diameter of ≥6 mm. In 10% of patients, even the mesopic pupil is ≥6 mm.

APPROX. 20 %
SCOTOPIC PUPIL DIAMETER ≥6 mm

APPROX. 10 %
MESOPIC PUPIL DIAMETER ≥6 mm

For an untroubled visual outcome

PREVENT PHOTIC PHENOMENA

  • Overlapping of the pupil with the IOL optic to prevent direct light passing the IOL and striking the retina directly, even with large pupil diameters
  • Incident light passes safely through the XL optic – including peripheral light incidence, which can be perceived as disturbing even with small pupils
  • Reduced interfering edge effects

Simulated beam guidance – 6.0 mm optic

Simulated beam guidance – 7.0 mm optic

Graphic based on a simulation using Optic Studio 16.5, Zemax with a 6 mm optic (1) and a 7 mm optic (2); pupil size – both 6 mm.

ASPIRA-aXA

ELIMINATING DYSPHOTOPSIAS

The ASPIRA-aXA with its enlarged XL optic represents a promising approach to prevent negative dysphotopsia.

UP TO 20% – NEGATIVE DYSPHOTOPSIA
Almost 20% of patients notice negative dysphotopsia after implantation of a standard IOL

UP TO 3% – PERSISTENT
Nearly 3% of pseudophakic patients are severely impaired by negative dysphotopsia permanently

Negative Dysphotopsia

MULTIFACTORIAL ORIGIN

Negative dysphotopsia can occur after successful cataract sugery with IOL implantation. The reasons for development of negative dysphotopsia in pseudophakic eyes seem to be multifactorial. Discussed are among others:

  • Material properties

    e. g. a high refractive index of the IOL material

  • Lens design

    e. g. IOL edge design, optic-haptic transitions

  • Physiological factors

    e. g. pupil size or depth of the anterior chamber

A model

FOR THE DEVELOPMENT OF NEGATIVE DYSPHOTOPSIA

Numerous ray tracing analyses using standard IOLs show a non-illuminated region of the peripheral nasal retina. This “shadow” is caused by the reduced optic diameter and the central thickness of the artificial IOL compared to the natural lens.

Schematic drawing modified according to Holladay

2.5 mm pupil, 6.0 mm IOL

 

The retinal image is generated by light rays refracted by the IOL optic (areal A), as well as by light rays that hit the retinal periphery (area B) either directly or indirectly refracted by the IOL edge. The unilluminated gap between these two areas can lead to the perception of negative dysphotopsia.

ASPIRA-aXA

CLINICALLY CONVINCING

0% Negative dysphotopsia

  • All patients included in the study stated that they perceived no negative dysphotopsia after one year

100% Patient satisfaction

  • All patients were either very satisfied or satisfied according to a patient survey after treatment with ASPIRA-aXA

Outstanding visual results

  • Median corrected distant visual acuity was 1.2 (decimal); 96% of the patients achieved corrected visual acuity of 0.8 (decimal) or better after one year

Pseudophakic reliability

WHAT IS THE ADVANTAGE OF AN XL OPTIC?

RISK
Approx. 20% – diabetes mellitus type 2
Cases in the age group of the average cataract patient
Over 65% – develop diabetic retinopathy
In the group of diagnosed diabetics within 20 years

REASONS
For visual impairment, according to WHO, are mainly

  • diabetic retinopathy
  • myopia (with the risk of developing high myopia including resulting secondary diseases)

TENDENCY
increasing
  • Prevalence of diabetes mellitus is expected to increase by 50% by 2045
  • 10% of the world’s population is estimated to suffer from high myopia by 2050

    • PREVENTION
    An investment to the future
  • Screening and therapy reduce the risk of irreversible visual consequences
  • Timeliness and regularity are crucial

    • The panoramic IOL

    KEEPING TRANSPARENCY

    From a vitreoretinal point of view, both the surgeon and the postoperative doctor benefit from the extended fundus view. The assessment of the posterior segment of the eye and the implementation of therapeutic measures for peripheral retinal diseases can occur more conveniently.

    ASPIRA-aXA offers patients with an increased risk of ocular diseases an advantage for long-term, successful pseudophakic treatment.

    FOR AN EXCELLENT
    INTRAOPERATIVE VIEW

    • Opening of the anterior capsule membrane with a rhexis diameter of up to 6.5 mm
    • Allows an extended fundus view for the long-term monitoring of patients at risk

    Intraoperative fundus image* (1) Edge of the XL optic (2) Theoretical optic edge of a 6.0 mm IOL

     

    Intraoperative image with implanted ASPIRA-aXA** (1) Edge of the XL optic (2) Rhexis: diameter 6.0 mm

    FOR AN CONVENIENT
    POSTOPERATIVE FOLLOW-UP

    • Extended fundus view for convenient assessment of the tissue structures of the posterior segment of the eye
    • Facilitates therapeutic measures in the presence of peripheral retinal diseases

    * Courtesy of Univ.-Prof. Dr. M. Bolz, Linz
    ** Courtesy of Prof. Dr. G. Duncker, Halle

    The panoramic IOL

    EXPERTS RECOMMEND

    Prof. W. Sekundo, Marburg
    “The large ASPIRA-aXA optic has proven itself in phaco-vitrectomies because it allows an edge-free view into the outer retinal periphery.”
    Personal Statement, 2018

    Univ.-Prof. Dr. Matthias Bolz, MD, Linz
    „The view into the periphery is not only important for standard funduscopy, but also for diagnostics, fluorescence angiography and above all for retinal surgery.”
    Die ASPIRA-aXA aus Sicht eines Retinologen. Presentation DOC (Internationaler Kongress der Deutschen Ophthalmochirurgen), HumanOptics Booth Lecture, Nuremberg, 2018.

    Y. Takamura, MD, PhD.
    “The creation of a larger capsulorhexis with implantation of a 7.0 mm optic IOL contributed to a larger anterior capsule opening after cataract surgery in patients with DM [diabetes mellitus].”
    Takamura, Y., et al. Large capsulorhexis with implantation of a 7,0 mm optic lens during cataract surgery in patients with diabetes mellitus. J Catract Refract Surg 2014; 40(11):1850-1856.

     

    Outstanding material meets best-in-class technology

    A MATERIAL TO WIN YOU OVER

    High transmission. High quality.

    • The ASPIRA-aXA achieves very high transmission levels
    • The high level of transmission attests excellent material quality, which is a crucial determinant of IOL image quality

    High Abbe number. High contrast sensitivity.*

    A high Abbe number, as a quality measure of the imaging properties of IOLs, is associated with

    • a reduction in chromatic aberrations in IOLs
    • higher image quality

    * Zhao, H., Mainster, M. (2007). The effect of chromatic dispersion on pseudophakic optical performance. Br J Ophthalmol. 91 (9):1225-1229.

    Easy application

    SAFE POSITIONING

    • QUATTRO POINT CONTACT ZONE

      For stable placement in the capsular bag

    • DOUBLE POSITION MARKING

      For correct and safe placement

    • CUT-OUT HAPTICS

      As absorption elements for embedding the IOL in the capsular bag

    Dr. J. Schrecker, Glauchau
    „Implantation can be performed with the same incision width as with a standard IOL.”
    Personal statement, 2018

    PROVEN TO BE ROTATIONALLY STABLE

    • Medium rotation four months postoperatively (n=23) is < 2,3° (2,28°± 1,84°)

    Choose

    – AS DESIRED.

    • Two models available

      – optional with blue-light protection

    • Conveniently

      – preloaded in SAFELOADER®

    • Space-saving

      – as COMPACT LINE

    7.0 mm optic – preloaded

    SAFELOADER®
    SIMPLE. INTUITIVE. FAST.

    The contactless preloaded implantation system offers a maximum of safety combined with its intuitive, easy handling.

    See for yourself!
    Reports from clinical application

    The space-saving model

    COMPACT LINE

    For space-saving storage even when space is at a premium – ideal for use in the inpatient sector

    Premium IOL ASPIRA-aXA

    Your advantages of the premium IOL platform

    Clinical performance

    What do the experts say?

    Dr. E. Becker/ M. Bonsemeyer, Oranienburg
    “The ASPIRA-aXA with its enlarged XL optic represents a promising approach to minimize dysphotopsia.”
    Piskula, M. Becker, E. (2018). Reduzierte pseudophake Dysphotopsien durch vergrößerte IOL-Optik. Presentation DGII 2018.

    Prof. G. Duncker, Halle
    “The patient response has been overwhelmingly positive.”
    Personal Statement, 2018

     

    Application

    Publications

    Reports from clinical application

    Wendelstein J, Laubichler P, Fischinger I, et al.
    Rotational Stability, Tilt and Decentration of a New IOl with a 7.0 mm Optic
    Current Eye Research 2021 Jun;14
    Click here for full report

    Borkenstein A. F., Borkenstein E. M.
    Creating Hybrid Monovision with 7.0 mm XL Optic and High-Add AMD Intraocular Lenses (XL-MAGS) in a Patient with Retinitis Pigmentosa
    Case Rep Ophthalmol 2019;10:304-311; doi: 10.1159/000503093
    Click here for full report

    ASPIRA-aXA

    Media reports

    Interview with Becker, E. & Schrecker, J.
    Improved Stability, Refractive Results With the Aspira-aXA IOL—A Novel IOL With Enlarged Optic Diameter
    Cataract Refractive Surgery Today Europe 2020; 03:23

    Click here for full article

    Interview with Bolz, M.
    aXA Good Question, Get a Good Answer
    The Ophthalmologist 2019;10:59

    Click here for full article

    This post is also available in: German

    OUR

    CUSTOMER SERVICE

    YOUR

    QUESTIONS

    Our experts support you with your questions at any time.

      *Mandatory field

      Honored: CUSTOMFLEX® ARTIFICIALIRIS receives Prix Galien nomination

      News
      News

      The CUSTOMFLEX® ARTIFICIALIRIS has been nominated for the biomedical industry’s most prestigious award, the Prix Galien. The award honors the technical, scientific and clinical know-how underlying the development of innovative medicines and medical devices, such as the CUSTOMFLEX® ARTIFICIALIRIS. 1 The unique iris implant makes a major contribution to the quality of life of aniridia […]

      Read more